MBRX

Quote

Short

News

Articles

Message Board

Moleculin Biotech Inc. (NASDAQ : MBRX ) News

Moleculin Biotech Inc. (NASDAQ: MBRX) News Releases

MBRX News Releases

June 05, 2026 08:29:00 am

GlobeNewswire

Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML

June 04, 2026 08:31:00 am

GlobeNewswire

Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor "What This Means" Segment

May 29, 2026 08:21:00 am

GlobeNewswire

Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits

May 21, 2026 05:02:00 pm

GlobeNewswire

Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin

May 15, 2026 08:34:37 am

SeekingAlpha

Moleculin Biotech GAAP EPS of -$3.54 misses by $2.08

May 15, 2026 08:30:00 am

GlobeNewswire

Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial

May 13, 2026 08:00:00 am

GlobeNewswire

Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks

May 12, 2026 09:30:00 am

GlobeNewswire

Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits

May 08, 2026 08:45:00 am

GlobeNewswire

Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin

April 23, 2026 08:25:00 am

GlobeNewswire

Moleculin's Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026

	Next 10

Subscribe to Our Newsletter

Download The Market Wire News App

Link Market Wire News to Your X Account